Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study

References

• Shadmi E, Chen Y, Dourado I, Faran-Perach I, Furler J, Hangoma P, Hanvoravongchai P, Obando C, Petrosyan V, Rao KD, et al. Health equity and COVID-19: global perspectives [Internet]. Int J Equity Health. 2020 [accessed 2021 Jun 21];19. /pmc/articles/PMC7316580/.
   Web of Science ®Google Scholar
• Khuroo MS, Khuroo M, Khuroo MS, Sofi AA, Khuroo NS. COVID-19 vaccines: a race against time in the middle of death and devastation! J Clin Exp Hepatol. 2020;10:610–8. doi:10.1016/j.jceh.2020.06.003.
   PubMed Web of Science ®Google Scholar
• Shepshelovich D, Yahav D, Ben Ami R, Goldvaser H, Tau N. Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study. J Antimicrob Chemother. 2021;76:2415–18. doi:10.1093/jac/dkab163.
   PubMed Web of Science ®Google Scholar
• Yoo JH. What we do know and do not yet know about COVID-19 vaccines as of the beginning of the year 2021. J Korean Med Sci. 2021;36. doi:10.3346/jkms.2021.36.e54.
   Google Scholar
• Mummert A, Weiss H, Long LP, Amigó JM, Wan XF. A perspective on multiple waves of influenza pandemics. PLoS One. 2013;8:e60343. doi:10.1371/journal.pone.0060343.
   PubMed Web of Science ®Google Scholar
• Randolph HE, Barreiro LB. Herd immunity: understanding COVID-19. Immunity. 2020;52:737–41. doi:10.1016/j.immuni.2020.04.012.
   PubMed Web of Science ®Google Scholar
• Jones D, Helmreich S. A history of herd immunity. Lancet. 2020;396:810–11. doi:10.1016/S0140-6736(20)31924-3.
   PubMed Web of Science ®Google Scholar
• Kaur SP, Gupta V. COVID-19 Vaccine: a comprehensive status report [Internet]. Virus Res. 2020 [accessed 2021 Aug 31];288: 198114. /pmc/articles/PMC7423510/.
   PubMed Web of Science ®Google Scholar
• Fortner A, First SD. COVID-19 vaccines receiving the US FDA and EMA emergency use authorization. Discoveries. 2021;9:e122. doi:10.15190/d.2021.1.
   Google Scholar
• World Health Organization. Coronavirus disease (COVID-19) [Internet]; 2021 [accessed 2021 May 30]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
   Google Scholar
• Jordan News Agency. JFDA approves emergency use of Sputnik COVID vaccine. (Petra); 2021. [internet]; [accessed 2021 May 30]. https://petra.gov.jo/Include/InnerPage.jsp?ID=32973&lang=en&name=en_news
   Google Scholar
• Doroftei B, Ciobica A, Ilie O-D, Maftei R, Mini-Review IC. Discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics (Basel). 2021;11(4):579.
   Google Scholar
• GOV.UK. Janssen publishes positive safety and efficacy data for single-dose COVID-19 vaccine [Internet]. GOV.UK2021; [ accessed 2021 May 30]. https://www.gov.uk/government/news/janssen-publishes-positive-safety-and-efficacy-data-for-single-dose-covid-19-vaccine?fbclid=IwAR0nmT5gGtldli6gEej-Vt8W9HfUEEU6DKP6xelHiYAVlwpa2HX6PKeMZtg.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. [Internet]. 2020 [accessed 2021 May 30];383:2603–15. https://www.nejm.org/doi/full/10.1056/nejmoa2034577.
   PubMed Web of Science ®Google Scholar
• Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27:205–11. doi:10.1038/s41591-021-01230-y.
   PubMed Web of Science ®Google Scholar
• Kimmel SR. Vaccine adverse events: separating myth from reality. Am Fam Physician. 2002;66(11):2113–20.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Reactions and adverse events of the pfizer-BioNTech COVID-19 vaccine | CDC [Internet]. Centers Dis Control Prev. 2020 [accessed 2021 May 30]. https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html.
   Google Scholar
• Centers for Disease Control and Prevention. Possible side effects after getting a COVID-19 vaccine | CDC [Internet]. Centers Dis Control Prev. 2021 [accessed 2021 May 30]. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html.
   Google Scholar
• Lee E, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, Semple JW, Arnold DM, Godeau B, Lambert MP, et al. Thrombocytopenia following Pfizer and moderna SARS‐CoV‐2 vaccination. Am J Hematol. [Internet]. 2021 [accessed. 2021 Aug 31];96:534–37. /pmc/articles/PMC8014568/.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets [Internet]; 2020 [accessed 2021 May 30]. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood.
   Google Scholar
• Vaccine adverse event reporting system (VAERS) [Internet]; [accessed 2021 Aug 31]. https://vaers.hhs.gov/.
   Google Scholar
• Yellow card scheme - MHRA [Internet]. [accessed 2021 Aug 31]. https://yellowcard.mhra.gov.uk/.
   Google Scholar
• UNHCR Jordan. COVID-19 vaccine [Internet]; 2020 [accessed 2021 Aug 31]. https://help.unhcr.org/jordan/en/frequently-asked-questions-unhcr/covid-19-vaccine/.
   Google Scholar
• Adorni F, Prinelli F, Bianchi F, Giacomelli A, Pagani G, Bernacchia D, Rusconi S, Maggi S, Trevisan C, Noale M, et al. Self-reported symptoms of SARS-CoV-2 infection in a nonhospitalized population in Italy: cross-sectional study of the EPICOVID19 web-based survey. JMIR Public Heal Surv. 2020;6(3):e21866.
   Google Scholar
• Nomura S, Yoneoka D, Shi S, Tanoue Y, Kawashima T, Eguchi A, Matsuura K, Makiyama K, Ejima K, Taniguchi T, et al. An assessment of self-reported COVID-19 related symptoms of 227,898 users of a social networking service in Japan: has the regional risk changed after the declaration of the state of emergency? Lancet Reg Heal West Pacific. 2020;1:11.
   Google Scholar
• Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21:939–49. doi:10.1016/S1473-3099(21)00224-3.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21:39–51. doi:10.1016/S1473-3099(20)30831-8.
   PubMed Web of Science ®Google Scholar
• Kim SH, Wi YM, Yun SY, Ryu JS, Shin JM, Lee EH, Seo KH, Lee SH, Peck KR. Adverse events in healthcare workers after the first dose of Chadox1 Ncov-19 Or Bnt162b2 Mrna Covid-19 vaccination: a single center experience. J Korean Med Sci. 2021;36:1–8.
   Web of Science ®Google Scholar
• Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10:1428. doi:10.3390/jcm10071428.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
   Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020;396:1979–93. doi:10.1016/S0140-6736(20)32466-1.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience): interim guidance, first issued 10 February 2021, updated 21 April 2021. World Health Organization. 2021 [accessed 2021 May 30]. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1.
   Google Scholar
• Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376–81. doi:10.1016/j.ijid.2021.04.047.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324:951. doi:10.1001/jama.2020.15543.
   PubMed Web of Science ®Google Scholar
• Wu Q, Dudley MZ, Chen X, Bai X, Dong K, Zhuang T, Salmon D, Yu H. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. Internet]. 2021 [accessed 2021 Aug 31]; 19:1–16. 2021 191. https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-021-02059-5.
   PubMed Web of Science ®Google Scholar
• McMurry R, Lenehan P, Awasthi S, Silvert E, Puranik A, Pawlowski C, Venkatakrishnan AJ, Anand P, Agarwal V, O’Horo JC, et al. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med (New York, NY). [Internet] 2021 [accessed. 2021 Aug 31];2. https://pubmed.ncbi.nlm.nih.gov/34230920/.
   Google Scholar
• Karasneh RA, Al-Azzam SI, Alzoubi KH, Rababah LK, Muflih SM. Health literacy and related health behaviour: a community-based cross-sectional study from a developing country. J Pharm Heal Serv Res. 2020;11:215–22. doi:10.1111/jphs.12370.
   Web of Science ®Google Scholar
• Fenner Y, Garland SM, Moore EE, Jayasinghe Y, Fletcher A, Tabrizi SN, Gunasekaran B, Wark JD. Web-based recruiting for health research using a social networking site: an exploratory study. J Med Internet Res. 2012;14:e20. doi:10.2196/jmir.1978.
   PubMed Web of Science ®Google Scholar
• Cantrell MA, Lupinacci P. Methodological issues in online data collection. J Adv Nurs. 2007;60:544–49. doi:10.1111/j.1365-2648.2007.04448.x.
   PubMed Web of Science ®Google Scholar
• Telecommunication regulatory commission (TRC). ICT facts and opportunities in Jordan [Internet]. Amman-Jordan. 2019 [accessed 2021 Aug 18]. https://www.trc.gov.jo/EchoBusV3.0/SystemAssets/PDF_Engilsh/768e5c53-6373-4d1e-924b-118eb311f2b4_ICTFacts&OpportunitiesinJordan_HI.pdf.
   Google Scholar
• Alaiad A, Alsharo M, Alnsour Y. The determinants of M-health adoption in developing countries: an empirical investigation. Appl Clin Inform. 2019;10:820. doi:10.1055/s-0039-1697906.
   PubMed Web of Science ®Google Scholar
• Yassin A, AlOmari M, Al-Azzam S, Karasneh R, Abu-Ismail L, Soudah O. Impact of social media on public fear, adoption of precautionary behaviors, and compliance with health regulations during COVID-19 pandemic. Int J Environ Health Res. 2021 Jun 7;1–13. 10.1080/09603123202119357782021.
   Google Scholar
• Sheldon P, Antony MG, Ware LJ. Baby Boomers’ use of Facebook and Instagram: uses and gratifications theory and contextual age indicators. Heliyon. 2021;7:e06670. doi:10.1016/j.heliyon.2021.e06670.
   PubMed Web of Science ®Google Scholar
• UNHCR. COVID-19 vaccination and implications for gender-based violence (GBV) prevention and response - GBV WG-Jordan [EN/AR] - Jordan | reliefWeb [Internet]. Guidance. 2021 [accessed 2021 Aug 18]. https://reliefweb.int/report/jordan/covid-19-vaccination-and-implications-gender-based-violence-gbv-prevention-and?fbclid=IwAR2NULhF-_lLi57HpWWZtZ6A3gDeV5P_rkMd3BVXD3YLa1eXI7RC_hgqflc.
   Google Scholar